

Drug Monograph

Drug/Drug **Intermezzo[®] (zolpidem tartrate) Tablet / Sedative-**
 Class: **Hypnotic**
 Prepared for: MO HealthNet
 Prepared by: ACS, A Xerox Company

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Intermezzo sublingual tablets are available in unit-dose pouches in 1.75 mg and 3.5 mg strengths.

Manufacturer: Purdue Pharma L.P. Stamford, CT 06901-3431

Indications: Intermezzo[®] sublingual tablets are indicated for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

Costs: \$6.45 per sublingual tablet of both strengths of Intermezzo Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications Under Solicitation

Prepared By: Katie Wilbers, Pharm.D.
 Date: April 16, 2012